This inventor holds 1 USPTO granted patent. Top assignee: University of Manitoba. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: The Innovative Contributions of Derek Ammeter
Introduction
Derek Ammeter is a notable inventor based in Winnipeg, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of new antibiotic potentiators. His work focuses on enhancing the efficacy of existing antibiotics against multidrug-resistant and extensively drug-resistant bacterial strains.
Latest Patents
Derek Ammeter holds a patent for his invention titled "Potentiation of β-lactam antibiotics and β-lactam/β-lactamase inhibitor combinations against multidrug and extensively drug-resistant using non-ribosomal tobramycin-cyclam conjugates." This patent describes the development of non-β-lactam-based potentiator molecules that synergize with β-lactam antibiotics and β-lactam-β-lactamase inhibitor combinations against MDR/XDR phenotypes. The compound features a chemical structure or formula of Formula (A) or a suitable salt form thereof, wherein 'n' is a carbon tether having a length of between about 2-18 carbons. He has 1 patent to his name.
Career Highlights
Derek Ammeter is affiliated with the University of Manitoba, where he conducts research and collaborates with other scientists. His work has been instrumental in addressing the challenges posed by antibiotic resistance, a growing concern in modern medicine.
Collaborations
Some of his notable coworkers include Temilolu Idowu and Frank Schweizer. Their collaborative efforts contribute to the advancement of research in the field of antibiotic development.
Conclusion
Derek Ammeter's innovative work in antibiotic potentiation highlights the importance of developing new strategies to combat antibiotic resistance. His contributions are vital for the future of effective treatments against resistant bacterial infections.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
